Aligos Therapeutics announced the completion of enrollment for both HBeAg+ and HBeAg- patient cohorts in its Phase 2 B-SUPREME trial for pevifoscorvir sodium, a treatment for chronic hepatitis B virus. This milestone indicates progress in the drug's development, with topline data expected in late Q3 2027, providing a long-term catalyst for the company.
Aligos Therapeutics has completed enrollment for its Phase 2 B-SUPREME trial, a significant step in the development of pevifoscorvir sodium for chronic hepatitis B. This matters because completing enrollment de-risks the trial timeline and moves the company closer to potential commercialization, which is a positive for shareholders. The company over-enrolled the HBeAg+ cohort, leading to the cancellation of a planned interim analysis, which could be interpreted as confidence in the trial's design or an acceleration of the process. While the immediate market impact might be moderate as topline data is still years away (late Q3 2027), this news provides a long-term positive catalyst for Aligos, signaling progress in its pipeline. The key opportunity for traders is the potential for future upside if the trial results are positive, but the long wait for data also presents a risk of prolonged uncertainty.